CARM (CARISMA Therapeutics) Total Liabilities: $7.42 Mil (As of Sep. 2025)


What is CARISMA Therapeutics Total Liabilities?

CARISMA Therapeutics CARM +5.17% Total Liabilities is $7.42 Mil as of Sep. 2025. The stock has 3 warning signs investors should review.

CARISMA Therapeutics's Total Liabilities for the quarter that ended in Sep. 2025 was $7.42 Mil.

CARISMA Therapeutics's quarterly Total Liabilities declined from Mar. 2025 ($52.62 Mil) to Jun. 2025 ($51.02 Mil) and declined from Jun. 2025 ($51.02 Mil) to Sep. 2025 ($7.42 Mil).

CARISMA Therapeutics's annual Total Liabilities declined from Dec. 2022 ($214.82 Mil) to Dec. 2023 ($63.02 Mil) and declined from Dec. 2023 ($63.02 Mil) to Dec. 2024 ($58.37 Mil).

CARISMA Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for CARISMA Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CARISMA Therapeutics Total Liabilities Chart

CARISMA Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Total Liabilities
8.31 9.43 214.82 63.02 58.37

CARISMA Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 53.18 58.37 52.62 51.02 7.42

CARISMA Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

CARISMA Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=16.055+(0.744+0.318
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+41.25+0+0)
=58.37

Total Liabilities=Total Assets (A: Dec. 2024 )-Total Equity (A: Dec. 2024 )
=30.458--27.909
=58.37

CARISMA Therapeutics's Total Liabilities for the quarter that ended in Sep. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=6.812+(0.609+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=7.42

Total Liabilities=Total Assets (Q: Sep. 2025 )-Total Equity (Q: Sep. 2025 )
=6.554--0.867
=7.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $7.42 Mil mean?
CARISMA Therapeutics (CARM) has a Total Liabilities of $7.42 Mil as of Sep. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for CARISMA Therapeutics and its competitors.
Is CARISMA Therapeutics' Total Liabilities too high?
CARISMA Therapeutics' current Total Liabilities is $7.42 Mil.
How does CARISMA Therapeutics' Total Liabilities compare to SCPX and CYTOF?
CARISMA Therapeutics' Total Liabilities of $7.42 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for CARISMA Therapeutics and its competitors. CARISMA Therapeutics's current Total Liabilities is $7.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CARISMA Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CARISMA Therapeutics (CARM) is currently considered Possible Value Trap. The stock's GF Value™ is $3.71, compared to a current price of $0.01 — trading 99.8% below its estimated fair value. The current Total Liabilities is $7.42 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For CARISMA Therapeutics (CARM), the current Total Liabilities is $7.42 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CARISMA Therapeutics Business Description

Address 3675 Market Street, Suite 200, Philadelphia, PA, USA, 19104
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.